Skip to content

Study · Observational study · n = 1,454 · 2016

5 results

Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).

Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E

Calcified tissue international30 Apr 2016Cited by 41 (Europe PMC)

PMID27137783 (opens in a new tab)PMCIDPMC4960288 (opens in a new tab)DOI10.1007/s00223-016-0143-5 (opens in a new tab)PepBankPUB-27137783
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the >18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In severe osteoporosis, 103 patients sustained 122 clinical fractures during teriparatide treatment, including vertebral and non-vertebral fractures.

    In plain wordsIn severe osteoporosis, clinical fractures occurred during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableIncident clinical fractures
    Study

    n = 1,454

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · median 23.7 monthsAs given in this study (human).

    Measurements

    Patients with fractures
    103 patients
    during treatment
    Patients with fractures
    7.1%
    during treatment
    Clinical fractures
    122 fractures
    during treatment
    Vertebral fractures
    21%
    incident clinical fractures
    Non-vertebral fractures
    79%
    incident clinical fractures

    Source sentences

    Summary
    During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral).
    1 context sentence
    Summary · context
    We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study.
  2. 02HumanObservational studyEfficacy outcome

    In severe osteoporosis, teriparatide treatment was linked to 49% lower fracture odds in the >18- to 24-month period versus the first period.

    In plain wordsIn severe osteoporosis, later teriparatide treatment was linked to lower fracture odds than the first treatment period.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOdds of clinical fractures
    Study

    n = 1,454

    Comparator
    First 6-month treatment period
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · median 23.7 monthsAs given in this study (human).

    Measurements

    Decrease in odds of fractures
    49%
    >18- to 24-month period versus first 6-month period

    Source sentences

    Summary
    A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the >18- to 24-month period versus the first 6-month period (both p < 0.05).
    1 context sentence
    Summary · context
    We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study.
  3. 03HumanObservational studyEfficacy outcome

    In severe osteoporosis, teriparatide treatment was linked to 75% lower vertebral fracture odds in the >18- to 24-month period.

    In plain wordsIn severe osteoporosis, later teriparatide treatment was linked to lower vertebral fracture odds than the first treatment period.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOdds of clinical vertebral fractures
    Study

    n = 1,454

    Comparator
    First 6-month treatment period
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · median 23.7 monthsAs given in this study (human).

    Measurements

    Decrease in odds of clinical vertebral fractures
    75%
    >18- to 24-month period versus first 6-month period

    Source sentences

    Summary
    A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the >18- to 24-month period versus the first 6-month period (both p < 0.05).
    1 context sentence
    Summary · context
    We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study.
  4. 04HumanObservational studyEfficacy outcome

    In severe osteoporosis, EQ-5D scores improved from baseline at each observation during teriparatide treatment.

    In plain wordsIn severe osteoporosis, teriparatide treatment was linked to better quality of life than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEQ-5D score
    Study

    n = 1,454

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · median 23.7 monthsAs given in this study (human).

    Source sentences

    Summary
    EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment.
    1 context sentence
    Summary · context
    We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study.
  5. 05HumanObservational studyEfficacy outcome

    In severe osteoporosis, back pain VAS scores improved from baseline at each observation during teriparatide treatment.

    In plain wordsIn severe osteoporosis, teriparatide treatment was linked to less back pain than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBack pain VAS
    Study

    n = 1,454

    Comparator
    Baseline
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated · median 23.7 monthsAs given in this study (human).

    Source sentences

    Summary
    EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment.
    1 context sentence
    Summary · context
    We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.